Industry news tidbits from around the world.
• In an attempt to stifle the spread of counterfeit drugs, Kenya has called upon intelligence units to catch counterfeiters through means similar to drug trafficking methods. Medical Services Minister Peter Anyang Nyongo said in a statement that his department plans to work with the National Security and Intelligence Services to improve surveillance methods and reduce the number of counterfeit drugs in Kenya, which, according to the country's National Quality Control Laboratories and the Pharmacy Poisons Board, make up about 30% of all drugs circulated throughout Kenya. Similarly, Rwanda is also looking at pharmacies across the country in an effort to determine the prevalence of counterfeit malaria drugs.
• A new World Trade Organization amendment may allow pharmaceutical companies to produce lower-cost generic antiretrovirals, malaria treatments, and other medicines for developing countries. Taiwan recently approved the first reading of the proposed amendment, which would facilitate the importation of cheaper, generic drugs to developing countries if they cannot manufacture the drugs themselves. Countries that have already approved the amendment are Australia, China, the European Union, Japan, South Korea, and the United States.
• Scientists in Germany and Russia are working in conjunction with researchers at the University of KwaZulu-Natal (Durban, South Africa) to create a database that could help shorten the diagnostic times of drug-resistant tuberculosis to a mere 48 hours.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.